Japanese companies used to have a well-deserved
reputation for being stodgy; while concepts like just-in-time inventory
were adopted relatively quickly, many companies have allowed themselves
to become lumbering conglomerates that are slow to jettison operations
with poor future prospects for growth or economic returns.
That's not so true with Fujifilm (OTCPK:FUJIY),
as this company has launched two significant transformations in the
past two decades - one designed to give the company life after the
decline of photographic film and a more recent one intended to offset
weakening prospects for office equipment. Fujifilm is arguably
underrated for its healthcare business and it is this part of Fujifilm
that has the best prospects for taking the business forward. Although
success in drug development is by no means assured, even modest
expectations would seem to support a fair value 10% higher than today's
price.
Follow this link for more:
Fujifilm's Long Transformation Process Heading In The Right Direction
No comments:
Post a Comment